Key Findings
Ultrahuman, a smart ring and wearable device company, has launched its new ‘M2 Live’ metabolic health platform in the U.S., integrating glucose data from Abbott’s over-the-counter (OTC) continuous glucose monitor (CGM) ‘Lingo.’ This service targets health-conscious adults aged 18 and older who do not use insulin, offering prescription-free, real-time glucose tracking starting at $99 per month. M2 Live, by partnering with the Lingo biosensor (wearable for up to 14 days), provides users with deep insights into how diet, exercise, sleep, and stress influence their blood sugar levels, thereby supporting personalized metabolic optimization.
Technical / Clinical Details
The M2 Live platform integrates glucose data from Abbott’s Lingo biosensor with Ultrahuman’s proprietary algorithms, correlating it with various lifestyle factors for comprehensive analysis. The Lingo sensor itself is designed for healthy adults aged 18 and above who do not use insulin and has been commercially available in the U.S. since 2024. The M2 Live app utilizes these continuous glucose readings to visualize blood sugar spikes and dips, and how they impact a user’s energy levels and overall metabolic health. The platform has been validated in collaboration with leading institutions such as Stanford University and Mayo Clinic, ensuring science-backed, personalized feedback.
Background & Context
In recent years, there has been a growing emphasis on preventive healthcare and personalized health management, with metabolic health becoming a critical focus within the wellness market. While CGM technology has primarily served diabetes management, the emergence of OTC products like Abbott Lingo has extended its benefits to a broader audience of health-conscious consumers. Ultrahuman’s M2 Live capitalizes on this trend by combining its existing wearable ecosystem, including smart rings, with CGM data, aiming to help users holistically understand their metabolism and drive behavioral change. This offers a novel approach to mitigating the risk of chronic diseases and enhancing overall wellness.
Strategic Significance & Outlook
The introduction of Ultrahuman M2 Live into the U.S. market is expected to intensify competition and accelerate innovation within the metabolic health monitoring sector. The integration of wearables and CGM data has the potential to create new business models in personalized nutrition and fitness. Users can now precisely understand how their bodies respond to specific diets and exercise regimens, enabling them to formulate more effective health strategies. Through this platform, Ultrahuman aims to empower individuals to optimize their health and performance, with potential future expansions to integrate data from other biosensors, offering even more comprehensive, biomarker-based health management solutions.
Source: https://cyborg.ultrahuman.com/press-releases/ultrahuman-launches-m2-live-abbotts-lingo
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments